Sutro Biopharma Inc (STRO) News

Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024

SOUTH SAN FRANCISCO, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company...

Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer

SOUTH SAN FRANCISCO, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

- Sutro will present updated data from the ongoing Phase 1b study of luvelta in combination with bevacizumab in...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Sutro Biopharma Appoints Dr. Barbara Leyman as Chief Business Development Officer

SOUTH SAN FRANCISCO, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities